Please login to the form below

Not currently logged in


This page shows the latest Spinraza news and features for those working in and with pharma, biotech and healthcare.

Still no breakthrough on Orkambi talks, MPs want answers

Still no breakthrough on Orkambi talks, MPs want answers

These have included those with Biogen on rare disease treatment Spinraza and Roche’s multiple sclerosis treatment.

Latest news

More from news
Approximately 15 fully matching, plus 19 partially matching documents found.

Latest Intelligence

  • #OrkambiNow? #OrkambiNow?

    But Orkambi is not the only orphan disease drug stuck in market access limbo in the England – Biogen’s Spinraza and BioMarin’s Kuvan are both currently suffering similar fates, and

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    only other SMA treatment available, Biogen’s Spinraza. ... The company argues that current ten- year costs of caring for SMA type 1 patients with Spinraza and additional care costs are somewhere between $2.5-$5m.

  • No incentive for a cure No incentive for a cure

    to 12-week course. And Spinraza from Biogen, the first ever disease-modifying treatment for spinal muscular atrophy (SMA), which increases the body’s ability to produce SMN protein critical to. ... And the lack of affordability - as well as the bad

  • The good, the bad and the ugly The good, the bad and the ugly

    Tecfidera (MS) and Spinraza (Spinal Muscular Atrophy) are expected to generate big sales, while Tysabril (MS and Crohn’s Disease) and Avonex (MS) are expected to see sales drop due to

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    2015 and in the EU 2016) and Spinraza (for the treatment of spinal muscular atrophy, only approved in the US).

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

The Exhibition Hall: Past, Present and Future
As I sit here at another pharma conference, I start to reflect on how they have changed over the years....
Success breeds success
This week we received the exciting news that we have been shortlisted for the Times Business Awards 2019, Tunbridge Wells in the 'Best Business 1-25 Employees' category....
Turning learning into action: The challenge of behaviour change